毕得医药公告称，2025年11月13日至12月19日，股东舟山兰旦企业管理合伙企业（有限合伙）及其一致 行动人吴波、舟山欣曦企业管理合伙企业（有限合伙）合计减持公司股份102.24万股，占总股本 1.12%。本次权益变动后，三者合计持股比例由11.12%降至10%，触及5%整数倍。本次减持系履行此前 计划，不触及要约收购，不会对公司治理及经营产生重大影响，减持计划尚未实施完毕。 ...

Investment Rating - The industry investment rating is "Overweight" [1] Core Views - The biopharmaceutical investment and financing environment has shown significant recovery since the second half of 2025, with a total financing amount of USD 30.32 billion from July to November 2025, representing a year-on-year increase of 30.90% [4] - The number of new drug IND applications stabilized in 2025, with approximately 1,897 applications from January to November, reflecting a year-on-year growth of about 7.91% [4] - The demand for CRO services has shown a clear turning point, and the report continues to recommend opportunities in the innovative drug industry chain (CXO + research services) for 2026 [4] Summary by Sections Industry Performance - The biopharmaceutical sector experienced a decline of 0.14% in the third week of December 2025, outperforming the CSI 300 index by 0.14 percentage points, ranking 22nd among 31 sub-industries [7][14] - The offline pharmacy sector saw the highest increase, rising by 5.59%, while the chemical preparation sector had the largest decline at 2.1% [18][22] Investment Opportunities - The report highlights the strong performance of leading CXO and research service companies, with many exceeding earnings expectations. Companies like WuXi AppTec and Tigermed have raised their earnings guidance for 2025 [5] - The report recommends a valuation switch opportunity for leading CXO and research service companies, given the continuous improvement in demand [5] Clinical Research Organizations (CRO) - There has been a notable improvement in orders for preclinical and clinical CROs, with expectations for significant improvements in financial statements for 2026 [6] - The report anticipates that the market demand will continue to focus on leading companies as the capacity of clinical CROs is expected to be streamlined [6] Monthly and Weekly Recommendations - The report recommends a monthly investment portfolio including companies such as Sanofi, Innovent Biologics, and others, focusing on innovative drug opportunities and valuation switch [8]

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4] Core Insights - The report highlights the promising data from CTLA-4 drugs, suggesting potential investment opportunities in related areas [3][5] - The pharmaceutical index experienced a slight decline of 0.14% from December 15 to December 19, 2025, but showed a relative outperformance of 0.14% against the CSI 300 index [5] - The report emphasizes the importance of innovative drugs as a key investment theme for 2026, with a focus on companies that are expected to show clear performance trends and potential reversals in operations [5][41] Summary by Sections 1. CTLA-4 Target - CTLA-4 is identified as a significant immune checkpoint that can inhibit T cell activation, presenting potential value in cancer immunotherapy [8][9] - The CTLA-4 monoclonal antibody Gotistobart shows promising clinical trial results for squamous non-small cell lung cancer (sqNSCLC) patients who are resistant to immunotherapy [14][15] - Gotistobart's innovative mechanism targets Treg cells in the tumor microenvironment, potentially leading to a new paradigm in tumor immunotherapy [20][24] 2. Industry Perspective - The report maintains that innovative drugs should be the main focus for the year, while also considering manufacturing exports and aging-related consumption as relatively undervalued assets [25][41] - The pharmaceutical index has shown a year-to-date increase of 14.49%, with a notable number of stocks experiencing significant gains [25][26] - The report suggests that the Chinese pharmaceutical industry has completed a transition from old to new growth drivers, with innovative drugs opening new growth avenues for companies [41][42] 3. Investment Recommendations - Recommended stocks include innovative drug companies such as Xinyi Tai, Zai Jian Pharmaceutical, and others, as well as companies in the medical device sector [5][45] - The report advises focusing on companies with strong performance trends and those expected to benefit from the aging population and outpatient consumption [42][44] - The report also highlights the potential of AI in the pharmaceutical sector, suggesting that related stocks may perform well in the coming years [42][44]

12月19日毕得医药大宗交易一览 证券时报·数据宝统计显示，毕得医药今日收盘价为64.50元，下跌0.29%，日换手率为1.91%，成交额为 5363.04万元，全天主力资金净流出73.98万元，近5日该股累计下跌4.43%，近5日资金合计净流出161.34 万元。 两融数据显示，该股最新融资余额为2827.16万元，近5日减少168.99万元，降幅为5.64%。 据天眼查APP显示，上海毕得医药科技股份有限公司成立于2007年04月27日，注册资本9088.2948万人 民币。（数据宝） 毕得医药12月19日大宗交易平台出现一笔成交，成交量8.66万股，成交金额519.75万元，大宗交易成交 价为60.00元，相对今日收盘价折价6.98%。该笔交易的买方营业部为中国银河证券股份有限公司金华证 券营业部，卖方营业部为浙商证券股份有限公司上海长乐路证券营业部。 进一步统计，近3个月内该股累计发生14笔大宗交易，合计成交金额为6574.76万元。 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） ...

毕得医药12月18日大宗交易平台共发生3笔成交，合计成交量16.74万股，成交金额1004.40万元。成交价 格均为60.00元，相对今日收盘价折价7.25%。从参与大宗交易营业部来看，机构专用席位共出现在1笔 成交的买方或卖方营业部中，合计成交金额为204.00万元，净买入204.00万元。 进一步统计，近3个月内该股累计发生13笔大宗交易，合计成交金额为6055.01万元。 两融数据显示，该股最新融资余额为2869.09万元，近5日减少268.76万元，降幅为8.57%。 据天眼查APP显示，上海毕得医药科技股份有限公司成立于2007年04月27日，注册资本9088.2948万人 民币。（数据宝） 12月18日毕得医药大宗交易一览 | 成交量 （万 | 成交金额 | 成交价 格 | 相对当日收盘 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | 股） | （万元） | （元） | 折溢价（%） | | | | 10.00 | 600.00 | 60.00 | -7.25 | 广发证券股份有限公司总部 | 浙商证券股份有限公司上 | | | ...

证券代码：688073 证券简称：毕得医药 公告编号：2025-090 上海毕得医药科技股份有限公司 股东减持计划时间届满暨减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持有的基本情况 本次股份减持计划实施前，上海毕得医药科技股份有限公司（以下简称"毕 得医药"或"公司"）股东李怡静持有公司无限售条件流通股 374,193 股，占公 司股份总数的 0.41%。股东陈俊持有公司无限售条件流通股 224,515 股，占公司 股份总数的 0.25%。股东李黎持有公司无限售条件流通股 224,515 股，占公司股 份总数的 0.25%。股东杜鹃持有公司无限售条件流通股 224,515 股，占公司股份 总数的 0.25%。股东李爱飞持有公司无限售条件流通股 217,032 股，占公司股份 总数的 0.24%。股东耿勇持有公司无限售条件流通股 149,675 股，占公司股份总 数的 0.16%。股东蒋亚妹持有公司无限售条件流通股 74,839 股，占公司股份总数 的 0.08%。李怡 ...

免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 截至发稿，毕得医药市值为59亿元。 每经头条（nbdtoutiao）——海南封关政策红利全解析：零关税、低个税、投资准入放宽、跨境资金自 由、创业扶持…… （记者 曾健辉） 每经AI快讯，毕得医药（SH 688073，收盘价：64.69元）12月18日晚间发布公告称，近日，公司收到李 怡静、陈俊、李黎、杜鹃、李爱飞、耿勇、蒋亚妹院出具的《关于股份减持结果的告知函》，前述人员 合计减持公司股份约44万股，占公司总股本的0.48%，本次减持计划时间区间已届满。 2024年1至12月份，毕得医药的营业收入构成为：研究和试验发展行业占比100.0%。 ...

毕得医药公告，公司股东李怡静、陈俊、李黎、杜鹃、李爱飞、耿勇、蒋亚妹于2025年9月18日至2025 年12月17日期间合计减持公司股份437,902股，占公司总股本的0.48%。其中，李怡静减持91,673股，减 持价格区间为75.00元/股至82.00元/股，减持总金额为7,245,513元；陈俊减持136,395股，减持价格区间 为70.56元/股至77.80元/股，减持总金额为9,931,500元；李黎减持10,000股，减持价格区间为66.65元/股 至82.20元/股，减持总金额为796,133元；杜鹃减持56,500股，减持价格区间为72.00元/股至76.00元/股， 减持总金额为3,800,000元；李爱飞减持63,255股，减持价格区间为78.50元/股至82.00元/股，减持总金额 为4,991,075元；耿勇减持32,119股，减持价格区间为65.20元/股至81.12元/股，减持总金额为2,404,480 元；蒋亚妹减持47,960股，减持价格区间为77.04元/股至79.03元/股，减持总金额为3,747,171元。 ...

南财智讯12月18日电，毕得医药公告，公司股东李怡静、陈俊、李黎、杜鹃、李爱飞、耿勇、蒋亚妹合 计减持公司股份437,902股，占公司总股本的0.48%。本次减持计划时间区间已届满，减持方式均为集中 竞价交易。上述股东在减持前合计持有公司1.64%的股份，减持完成后持股比例相应减少。本次实际减 持情况与此前披露的减持计划一致，未设置最低减持数量和比例，不存在违反承诺的情况。 ...

第3笔成交价格为60.00元，成交3.34万股，成交金额200.40万元，溢价率为-7.25%，买方营业部为瑞银 证券有限责任公司上海花园石桥路证券营业部，卖方营业部为浙商证券股份有限公司上海长乐路证券营 业部。 进一步统计，近3个月内该股累计发生13笔大宗交易，合计成交金额为6055.01万元。该股近5个交易日 累计下跌3.45%，主力资金合计净流出501.35万元。 责任编辑：小浪快报 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 12月18日，毕得医药收跌1.57%，收盘价为64.69元，发生3笔大宗交易，合计成交量16.74万股，成交金 额1004.4万元。 第1笔成交价格为60.00元，成交10.00万股，成交金额600.00万元，溢价率为-7.25%，买方营业部为广发 证券股份有限公司总部，卖方营业部为浙商证券股份有限公司上海长乐路证券营业部。 第2笔成交价格为60.00元，成交3.40万股，成交金额204.00万元，溢价率为-7.25%，买方营业部为机构 专用，卖方营业部为浙商证券股份有限公司上海长乐路证券营业部。 ...